Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Astria Therapeutics, Inc. ATXS NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
50/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$22.50
+78.9%

Astria Therapeutics, Inc. (ATXS) is a Biotechnology company in the Healthcare sector, currently trading at $12.58. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ATXS = $23 (+78.9% upside).

Net income is $94M (loss), growing at -47.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $5M against $319M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 17.49 (strong liquidity). Debt-to-assets is 1.6%. Total assets: $342M.

Analyst outlook: 3 / 8 analysts rate ATXS as buy (38%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 34/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$22.50
▲ 78.86% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Astria Therapeutics, Inc., the average price target is $22.50, with a high forecast of $25.00, and a low forecast of $20.00.
Highest Price Target
$25.00
Average Price Target
$22.50
Lowest Price Target
$20.00

ATXS SharesGrow Score Overview

60/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 34/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ATXS

✓
VALUE Pass
100/100
ATXS trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $23, implying +82.8% from the current price $13. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ATXS: +0%/yr revenue is, -47.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ATXS: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 17.49 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
34/100
ATXS: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 34/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 3 / 8 analysts rate ATXS as buy (38%). Analyst consensus target is $23 (+82.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range3.555-13.29
Volume3.06M
Avg Volume (30D)1.07M
Market Cap$718.13M
Beta (1Y)0.02
Share Statistics
EPS (TTM)-1.67
Shares Outstanding$56.16M
IPO Date2015-06-25
Employees78
CEOJill C. Milne
Financial Highlights & Ratios
EBITDA$-94.26M
Net Income$-94.26M
Operating Income$-111.56M
Total Cash$328.13M
Total Debt$5.35M
Net Debt$-54.47M
Total Assets$342.36M
Price / Earnings (P/E)-7.5
Analyst Forecast
1Y Price Target$22.50
Target High$25.00
Target Low$20.00
Upside+78.9%
Rating ConsensusHold
Analysts Covering8
Buy 38% Hold 63% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS04635X1028

Price Chart

Track all markets on TradingView
ATXS
Astria Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
3.56 52WK RANGE 13.29

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 IRON
IRON
Disc Medicine, Inc.
$70.48
+2.95%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 OLMA
OLMA
Olema Pharmaceuticals, Inc.
$16.30
+2.32%
 LRMR
LRMR
Larimar Therapeutics, Inc.
$4.87
+0.21%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 OBIO
OBIO
Orchestra BioMed Holdings, Inc.
$4.51
+4.88%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message